We offer a wide range of support and services to market access and HEOR teams from global to local level, including: evidence and market access strategy development; the generation and assimilation of evidence; and implementation and communication to payers and other stakeholders. Our team of in-house market access consultants, health economists, writers, analysts and developers are experienced and skilled, and ready to help you with your latest market access challenge. We have access to a broad network of payers, clinicians and other stakeholders across global markets, who we regularly engage to inform our insights and recommendations.
At Mtech Access we are always striving to engage with the wider market access community and share our thoughts on the latest industry issues or methods development.
Should NICE consider a broader societal perspective when assessing new gene therapies?
Dan Howard and Hannah Gillies from our Health Economics team explore some of the themes from a recent Health Affairs Blog article on the implications of new cell and gene therapies on HTA: ‘Putting The Costs And...